Tag: Immunotherapy
COVID Vaccine Before ICI Initiation Tied to Increased Survival in Patients With Cancer
SARS-CoV-2 mRNA vaccination within 100 days of ICI initiation was associated with increased overall survival in patients with NSCLC or metastatic melanoma
Recurrence-Free Survival Longer With Nivolumab Than Ipilimumab in Melanoma
Median duration of recurrence-free survival was 61.1 months with nivolumab and 24.2 months with ipilimumab
Antithymocyte Globulin Cuts Loss of β-Cell Function in Type 1 Diabetes
ATG 2.5 and 0.5 mg/kg reduces loss of β-cell function in young people with recent-onset type 1 diabetes
Stapokibart Found to Be Superior to Placebo for Severe Chronic Rhinosinusitis With Polyps
Benefits include reduced polyp size and severity of nasal symptoms at 24 weeks
High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma
Complete response rate was 37 percent, and post-hoc end point of objective response rate was 89 percent
Sustained Clinical Benefit Seen for Pembrolizumab + Axitinib in Advanced Renal Cancer
Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo versus sunitinib
Patients With Leukemia Have Higher Infection Risk During Immunoglobulin Replacement Therapy
Finding seen for patients with chronic lymphocytic leukemia receiving immunoglobulin replacement therapy regularly
Rituximab Not Superior to Conventional Strategy for Eosinophilic Granulomatosis With Polyangiitis
Rituximab no better than glucocorticoids alone for inducing remission in patients with eosinophilic granulomatosis with polyangiitis
Guselkumab Efficacious for Moderately to Severely Active Crohn Disease in Adults
Both guselkumab regimens superior to placebo
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
80 percent of adult patients with stage III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment
